Cases

ACCEPTED 15-25-00088-CV FIFTEENTH COURT OF APPEALS AUSTIN, TEXAS 7/31/2025 12:13 PM No. 15-25-00088-CV CHRISTOPHER A. PRINE

ACCEPTED 15-25-00088-CV FIFTEENTH COURT OF APPEALS AUSTIN, TEXAS 6/24/2025 2:15 PM No. 15-25-

ACCEPTED 15-25-00088-CV FIFTEENTH COURT OF APPEALS AUSTIN, TEXAS 8/20/2025 6:36 PM

ACCEPTED 15-25-00088-CV FIFTEENTH COURT OF APPEALS AUSTIN, TEXAS 8/18/2025 3:30 PM No. 15-25-00088-CV CHRISTOPHE

ACCEPTED 15-25-00088-CV FIFTEENTH COURT OF APPEALS AUSTIN, TEXAS 7/10/2025 12:50 PM No. 15

ACCEPTED 15-25-00088-CV FIFTEENTH COURT OF APPEALS AUSTIN, TEXAS 7/31/2025 5:27 PM No. 15-25-00088-CV CHRISTOPHER A. PRINE

ACCEPTED 15-25-00088-CV FIFTEENTH COURT OF APPEALS AUSTIN, TEXAS 7/31/2025 12:08 PM No. 15-25-00088-CV CHRISTOPHER A. PRINE

ACCEPTED 15-25-00088-CV FIFTEENTH COURT OF APPEALS AUSTIN, TEXAS 5/30/2025 3:21 PM No. 15-25-

ACCEPTED 15-25-00088-CV FIFTEENTH COURT OF APPEALS AUSTIN, TEXAS 5/9/2025 3:24 PM No. ___________ CHRISTOPHER A. PRINE

ACCEPTED 15-25-00088-CV FIFTEENTH COURT OF APPEALS AUSTIN, TEXAS 6/4/2025 10:37 AM NO. 15-25-00088-CV

MEMORANDUM OPINION COLLEEN KOLLAR-KOTELLY, District Judge. Plaintiff AstraZeneca Pharmaceuticals LP (“AstraZeneca”) holds new drug applications for SEROQUEL® (“Seroquel”) and SEROQUEL XR® (“Seroquel XR”), antipsychotic drugs used te treat serious psychological disorders such as schizophrenia. Since AstraZeneca first obtained approval to market these drug

HOWARD, Circuit Judge. AstraZeneca Pharmaceuticals LP (“AstraZeneca”) appeals from the judgment of the district court, entered after a lengthy bench trial, of liability for unfair and deceptive business practices in violation of Massachusetts General Laws Chapter 93A (“Chapter 93A”). In re Pharm. Indus. Average Wholesale Price Litig., 491 F.Supp.2d 20 (D.Mass.2007). The district court found that AstraZeneca had caused

ACCEPTED 15-25-00088-CV FIFTEENTH COURT OF APPEALS November 21, 2025 AUSTIN, TEXAS 8/18/2025 3:30 PM

ACCEPTED 15-25-00088-CV FIFTEENTH COURT OF APPEALS AUSTIN, TEXAS

Petition for Writ of Mandamus Granted and Opinion filed November 21, 2025. In The Fifteenth Court of Appeals NO. 15-25-00088-CV IN RE ASTRAZENECA PHARMACEUTICALS LP, Relator ORIGINAL PROCEEDING WRIT OF MANDAMUS 71st District Court Harrison County, Texas Trial

351 S.W.3d 168 (2009) 2009 Ark. 547 Louise DePRIEST, Iva Duncan, Gladys Eaton, Carolyn Knight, Geraldine Harris, Bernice Milam, Wanda Hamilton, Eddie Lou Sanders, and Lisa Sanders, Appellants, v. ASTRAZENECA PHARMACEUTICALS, L.P.; AstraZeneca, PLC; Zeneca, Inc.; and AstraZeneca U.S., Appellees. No. 08-1257. Supreme Court of Arkansas. November 5, 2009.

Appellate Case: 24-4114 Document: 49-1 Date Filed: 07/23/2026 Page: 1 FILED United States Court of Appeals PUBLISH Tenth Circuit UNITED STATES COURT OF APPEALS July 23, 2026

USCA4 Appeal: 25-1056 Doc: 126 Filed: 03/31/2026 Pg: 1 of 70 PUBLISHED UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT No. 25-1054 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA, Plaintiff – Appellee, v. JOHN B. MCCUSKEY, in his offic

United States Court of Appeals FOR THE DISTRICT OF COLUMBIA CIRCUIT Argued May 5, 2026 Decided August 18, 2026 No. 25-5425 TEVA PHARMACEUTICALS USA, INC., ET AL., APPELLANTS v. ROBERT F. KENNEDY, JR., IN HIS OFFICIAL CAPACITY AS SECRETARY OF HEALTH AND HUMAN SERVICES AND MEHMET OZ, IN HIS OFFICIAL CAPACITY AS ADMINISTRATOR OF THE CENTERS FOR MEDICARE & MEDICAID SERVICES,

Opinion & Order BARBARA S. JONES, District Judge. *387TABLE OF CONTENTS INTRODUCTION. CO CO o I. The Parties. CO CO o II. The Patents-In-Suit. 03 05 CO A. Patent Ownership. CO CO III. The Pleadings. CO CO A. Complaint Against Mylan/Esteve.